Banco Bilbao Vizcaya Argentaria S.A. Acquires New Stake in BioNTech SE (NASDAQ:BNTX)

Banco Bilbao Vizcaya Argentaria S.A. acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,969 shares of the company's stock, valued at approximately $786,000.

A number of other hedge funds also recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock worth $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares during the period. Allianz SE purchased a new position in BioNTech in the 4th quarter worth $90,000. GAMMA Investing LLC boosted its position in BioNTech by 48.2% during the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company's stock valued at $105,000 after buying an additional 300 shares during the period. Finally, Generali Investments CEE investicni spolecnost a.s. purchased a new stake in BioNTech during the fourth quarter valued at about $137,000. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Down 1.7 %

Shares of NASDAQ:BNTX traded down $1.72 during trading on Thursday, hitting $102.43. The stock had a trading volume of 984,983 shares, compared to its average volume of 910,259. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a market capitalization of $24.58 billion, a PE ratio of -48.78 and a beta of 1.07. The firm's fifty day moving average is $100.82 and its 200 day moving average is $110.34.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm's quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.90 earnings per share. Analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on BNTX. Morgan Stanley lowered their target price on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. HC Wainwright lowered their price objective on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Citigroup started coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price on the stock. Truist Financial assumed coverage on shares of BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price target for the company. Finally, BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.